Protection From Retinopathy and Other Complications in Patients With Type 1 Diabetes of Extreme Duration
Jennifer K. Sun(Joslin Diabetes Center), George L. King(Joslin Diabetes Center), Alessandro Doria(Harvard University), David R. Sell(Case Western Reserve University), Bela F. Asztalos(Tufts University), Jerry D. Cavallerano, Lloyd Paul Aiello(Joslin Diabetes Center), Vincent M. Monnier(Case Western Reserve University), Christopher Strauch(Cleveland Clinic Lerner College of Medicine), Ernst J. Schaefer(Tufts University), Hillary A. Keenan(Joslin Diabetes Center)
Cited by 259
Related Papers
Vascular Endothelial Growth Factor in Ocular Fluid of Patients with Diabetic Retinopathy and Other Retinal Disorders
|New England Journal of Medicine|1994|3.8k
Suppression of retinal neovascularization in vivo by inhibition of vascular endothelial growth factor (VEGF) using soluble VEGF-receptor chimeric proteins.
|Proceedings of the National Academy of Sciences|1995|1.3k
Retinopathy in Diabetes
|Diabetes Care|2004|1.1k
Activation of Protein Kinase C Isoforms and Its Impact on Diabetic Complications
|Circulation Research|2010|979